The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

CEO Larry Ellison’s claims that artificial intelligence (AI) could help develop messenger RNA-based (mRNA) vaccines to cure ...

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.

Now, management expects 2025 revenue to fall into a range between $1.5 billion ... about $9.5 billion in cash to fund operations. Moderna shares have been beaten down a long way, and by some ...

FILE - A local resident receives the Moderna COVID-19 vaccine shot at a center, June 30, 2021, in the Sumida ward of Tokyo. (AP Photo/Eugene Hoshiko, File)(Eugene Hoshiko / AP) Moderna cut its ...